Anthera Pharmaceuticals Inc. (NASDAQ:ANTH)’s share price traded down 6.1% on Wednesday . The stock traded as low as $3.20 and last traded at $3.21, with a volume of 298,013 shares changing hands. The stock had previously closed at $3.42.

Several equities analysts recently weighed in on the stock. Jefferies Group reissued a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Wednesday, August 10th. Zacks Investment Research cut shares of Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. HC Wainwright assumed coverage on shares of Anthera Pharmaceuticals in a research note on Friday, July 8th. They issued a “buy” rating and a $10.00 target price for the company. Finally, FBR & Co reissued a “hold” rating on shares of Anthera Pharmaceuticals in a research note on Monday, June 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Anthera Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $9.58.

The company’s market capitalization is $140.02 million. The company has a 50-day moving average price of $3.22 and a 200-day moving average price of $3.41.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.04. Equities analysts predict that Anthera Pharmaceuticals Inc. will post ($1.37) EPS for the current year.

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.